When might it be more advantageous to use transcript-based therapies over gene editing therapies such as CRISPR/Cas?
a. When complete deletion or mutation of a gene would have deleterious effects
b. When targeted tissues are difficult to reach with standard vectors used for delivery
c. When standard vectors used for delivery of exogenous nucleic acid are too small
d. When mutations in multiple genes are involved in producing the disease phenotype
e. When you want highly-specific binding to the target strand